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The earliest well-documented case of porphyria is that of
King George III of England. In 1811, he was described
to have abdominal pain, tachycardia, discolored urine, and
‘‘madness’’. He was permanently affected by this condition
from 1811 until his death in 1820. Between 1911 and 1983,
all the known types of porphyria were described (Nordmann
et al, 1983; Mascaro and Lim, 2000). Because of the pres-
ence of phototoxic porphyrins, all cutaneous porphyrias are
associated with photosensitivity. The non-cutaneous po-
rphyrias, 5-aminolevulinic acid (ALA) dehydratase deficien-
cy porphyria and acute intermittent porphyria, do not have
cutaneous findings. This is due to the fact that the defective
enzymes in these two types of porphyria, ALA dehydratase
and porphobilinogn deaminase, respectively, are enzymes
that appear early in the heme biosynthic pathway; therefore,
the substrates for these enzymes are non-phototoxic po-
rphyrin precursors.
Erythropoietic protoporphyria (EPP) was first described
by Professor Ian Magnus, a photodermatologist at St John’s
Institute of Dermatology in London in 1961 (Magnus et al,
1961). His patient had pain following sun exposure; pro-
toporphyrin was present in his erythrocytes and bone mar-
row. The action spectrum of induction of lesions on the skin
was in the Soret band region (400–410 nm), consistent with
the absorption spectrum of protoporphyrin. Since this orig-
inal description, EPP has been reported from around the
world. It is the second most common type of cutaneous
porphyria after porphyria cutanea tarda (PCT). It is now
known that the abnormal porphyrin profile seen in EPP is
due to defective ferrochelatase, the last enzyme in the heme
biosynthetic pathway. Ferrochelatase catalyzes the inser-
tion of ferrous iron into protoporphyrin IX to form heme. The
cDNA encoding this enzyme has been cloned, and the gene
has been mapped to chromosome 18q22 (Nakahashi et al,
1990; Whitcombe et al, 1991).
EPP usually manifests itself in childhood. Patients com-
plain of burning and stinging sensations upon exposure to
sunlight, frequently associated with cutaneous edema. With
repeated exposure, purpura of the exposed areas, most
commonly dorsum of hands and forearms, and waxy thick-
ening of the knuckles and metacarpophalangeal and inter-
phalangeal joints can occur. Shallow, pitted scars occur on
frequently sun-exposed areas, especially the forehead and
nose bridge. Vesicles, erosion, and crusting are observed
only rarely, usually following extensive sun exposure. As
with many other photodermatoses, EPP tends to be active
in the spring and summer months, and well controlled dur-
ing the winter.
There are several factors that contribute to the develop-
ment of cutaneous lesions in EPP. Protoporphyrin, upon
exposure to Soret band radiation, is known to generate re-
active oxygen species, which in turn could result in lipid
peroxidation of the cell membranes, resulting in the lysis of
cells (Goldstein and Harber, 1972). Using purified mast cells
as a model, it has been demonstrated that protoporphyrin
and Soret band radiation induce the release of mast cell-
derived mediators; this process could be downregulated by
the presence of catalase, which inactivates hydrogen per-
oxide (Lim et al, 1987). In patients with EPP, there is thick-
ening of the capillary endothelial cell walls, manifested by
positive periodic acid-Schiff staining. Exposure to Soret
band radiation has been shown to result in lysis of the
endothelial cells (Schnait et al, 1975). Electromicroscopic
examination showed that the thickened endothelial cell wall
consisted of multiple layering of the basal lamina of the
endothelial cells. In a protoporphyric mouse model, it has
been demonstrated that the chronic exposure to Soret band
radiation resulted in repeated lysis of the endothelial cells,
with intact basal lamina. Upon regeneration of these cells,
multiple layering of basal lamina would then take place
(Ho¨nigsmann et al, 1976). b-carotene, a commonly used
therapeutic modality for the management of patients with
EPP during the summer months, is a quencher of oxygen-
free radicals. Its therapeutic efficacy in EPP, reported in
some studies, is supportive evidence for the role of reactive
oxygen species in the pathogenesis of cutaneous lesions in
this condition (Mathews-Roth et al, 1974).
Inflammatory cells and soluble mediators of inflammation
have also been shown to play a role in this process. In vitro,
protoporphyrin and Soret band radiation could induce the
release of mast cell-derived mediators (Lim et al, 1987). It
should be noted that this process does not occur when
uroporphyrin is used. This is probably a reflection of the
physical and chemical properties of these two types of por-
phyrins. Protoporphyrin is a 2-carboxyl porphyrin, which is
lipophilic; in contrast, the 8-carboxyl uroporphyrin is a hy-
drophilic porphyrin. This may explain the differences in the
clinical manifestations of patients with EPP, in which pro-
toporphryin is the predominant elevated porphyrin, and
those of patients with PCT, in which uroporphyrin is the
predominant porphyrin. Patients with EPP present with cu-
taneous erythema, urticarial lesions, and edema, where
mast cell-derived mediators might play a significant con-
tributory role. The lack of direct effect of uroporphyrin on
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mast cells may partly explain the manifestations of PCT, in
which patients present with skin fragility and bulla forma-
tion, without erythema and edema. The differences between
the physical and chemical properties of protoporphyrin and
uroporphyrin also explain the differences in the urinary po-
rphyrin profile of these two types of porphyrias. In EPP, uri-
nary porphyrin is negative. In contrast, in PCT, hydrophilic
uroporphyrin and 7-carboxyl porphyrin are routinely elevat-
ed in the urine.
In an animal model, polymorphonucler cells have also
been known to play a role in porphyrin-induced photo-
toxicity. In leukopenic animals, the phototoxic response was
suppressed (Lim et al, 1985). The complement system is
another mediator of inflammation that has been shown to
play a pathogenic role. In the presence of either pro-
toporphyrin or uroporphyrin, in vitro exposure to Soret band
radiation resulted in the activation of the complement sys-
tem, and the generation of anaphylatoxins (Lim and Gigli,
1981; Lim et al, 1981). In vivo exposure to Soret band ra-
diation of skin of patients with EPP and PCT also resulted in
the generation of anaphylatoxins (Lim et al, 1984).
The role of mast cells, leukocytes and the complement
system have been explored in detail in animal models. Po-
rphyrin-induced phototoxicity was associated with an in-
crease in serum histamine levels (He et al, 1989); the
phototoxic response was suppressed in skin sites where
mast cells had been degranulated by interdermal injection
of compound 48/80 performed prior to irradiation (Lim et al,
1985). Leukopenic animals, complement-depleted animals,
and animals congenitally deficient of the fifth component of
complement had markedly diminished porphyrin-induced
phototoxicity (Lim et al, 1981, 1985).
In vitro, increased synthesis of collagen by fibroblasts
has been reported following incubation with uroporphyrin;
this occurred in the absences of radiation (Varigos et al,
1982). This observation may serve as a partial explanation
for the development of sclerodermoid skin changes ob-
served in some patients with PCT; it is well recognized that
these sclerodermoid changes occur both in sun-exposed as
well as sun-protected areas of the skin.
In the current issue of the JID, Pawliuk et al (2004) el-
egantly demonstrated that elevated erythrocyte and plasma
protoporphyrin levels alone are not sufficient to induce the
development of cutaneous lesions in mice. The authors
transplanted bone marrow from BALB/C-FechmlPas mice, an
EPP mouse model, to normal recipients. They demonstrat-
ed that although the recepients developed markedly ele-
vated levels of protoporphyrin in the erythrocytes as well as
in the plasma, these animals did not develop cutaneous
photosensitivity, nor did they develop any evidence of he-
patic damage. The authors suggest that the normal dermal
and hepatic ferrochelatase levels prevented the develop-
ment of these changes. To confirm this hypothesis, they
were able to demonstrate that photosensitivity did not de-
velop in skin transplanted from normal mice to the back of
EPP mice. These findings not only increase our under-
standing of the pathophysiology of cutaneous lesions EPP,
they also provide a foundation for potential therapy. Topical
delivery of the defective enzyme, ferrochelatase, could po-
tentially restore the enzymatic activity in the dermis of EPP
patients, hence minimizing their phototoxicity. The success
of this therapeutic strategy would usher in a new and ex-
citing era for patients with EPP and those with other types
of cutaneous porphyrias, and for all of us who care for these
patients.
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